【ChiCTR2500112638】A pilot, open-label case series on the efficacy and safety of a synbiotic formula (HQP08) in preventing and managing chemotherapy-induced alopecia in cancer patients
ChiCTR2500112638
尚未开始
/
/
/
2025-11-17
/
/
Chemotherapy-induced alopecia in cancer patients
A pilot, open-label case series on the efficacy and safety of a synbiotic formula (HQP08) in preventing and managing chemotherapy-induced alopecia in cancer patients
A pilot, open-label case series on the efficacy and safety of a synbiotic formula (HQP08) in preventing and managing chemotherapy-induced alopecia in cancer patients
- To explore the efficacy and safety of a synbiotic formula (HQP08) in preventing and managing chemotherapy-induced alopecia in cancer patients - To study the compositional and functional changes in gut microbiome
病例对照研究
其它
None
None
GenieBiome Limited
/
6
/
2025-11-17
2027-11-16
/
Inclusion Criteria: •Individuals aged 18 - 60 who is newly diagnosed with stage I, II or III cancer •Planned chemotherapy to be completed within 6 months •Literate and can complete the self-report questionnaires •Able to understand the consent and sign the informed consent form；
请登录查看Exclusion Criteria: •Metastatic cancers with life expectancy <6 months •Pre-existing female-pattern or male-pattern baldness •History of hair transplantation, psoriasis or severe scalp infection •Undergoing or plan to receive scalp cooling •Plan for immunotherapy •Severe cardiac, hepatic, renal, pulmonary and haematic lesions or other life-threatening conditions •Known pregnancy or lactating •Use of antibiotics, probiotics or prebiotics in the last 4 weeks •History of allergy to probiotics or lactose •History of chemotherapy for other conditions；
请登录查看Geniebiome Limited
/
Geniebiome Limited的其他临床试验
GenieBiome Limited的其他临床试验
最新临床资讯
-
Nature子刊| 恒瑞HER2 ADC：81.5%患者肿瘤缓解，为何病理“清零”仅3.1%？
医药速览2026-08-31
-
首个！安进降脂药临床III期结果积极
医药速览2026-08-31
-
欧康维视2026-08-31
-
摩熵医药2026-08-31
-
摩熵医药2026-08-31
-
氨基观察2026-08-31
-
瞭望财经2026-08-31
-
药时代2026-08-31
-
Cytiva学堂2026-08-31
-
癌度2026-08-31
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-31
-
2026-08-31
-
2026-08-31
-
摩熵咨询 20 8
-
摩熵咨询 34 38
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-31
-
2026-08-31
-
2026-08-31
-
摩熵咨询 35 47
-
摩熵咨询 28 48
-
摩熵咨询 34 28
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29